NewLink Genetics Corporation (NASDAQ:NLNK) had its target price increased by Stifel Nicolaus from $14.00 to $29.00 in a research note published on Monday morning, MarketBeat reports. The firm currently has a buy rating on the biotechnology company’s stock.

NLNK has been the subject of a number of other research reports. Cantor Fitzgerald reaffirmed a buy rating and set a $26.00 target price on shares of NewLink Genetics Corporation in a report on Friday, September 8th. ValuEngine raised NewLink Genetics Corporation from a strong sell rating to a sell rating in a report on Thursday, September 7th. Zacks Investment Research raised NewLink Genetics Corporation from a sell rating to a hold rating in a report on Saturday, July 29th. Jefferies Group LLC raised NewLink Genetics Corporation from a hold rating to a buy rating and lifted their target price for the company from $7.00 to $26.00 in a report on Friday, September 8th. Finally, Robert W. Baird lowered NewLink Genetics Corporation from an outperform rating to a neutral rating and reduced their target price for the company from $25.00 to $8.00 in a report on Thursday, June 8th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $24.17.

Shares of NewLink Genetics Corporation (NASDAQ NLNK) opened at 13.74 on Monday. The firm’s 50-day moving average is $8.00 and its 200-day moving average is $12.84. The firm’s market capitalization is $404.24 million. NewLink Genetics Corporation has a 52 week low of $5.90 and a 52 week high of $25.17.

NewLink Genetics Corporation (NASDAQ:NLNK) last posted its earnings results on Friday, July 28th. The biotechnology company reported ($0.57) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.78) by $0.21. The business had revenue of $10.37 million during the quarter, compared to analyst estimates of $2.65 million. NewLink Genetics Corporation had a negative return on equity of 55.03% and a negative net margin of 161.94%. Equities analysts anticipate that NewLink Genetics Corporation will post ($2.82) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This report was originally reported by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/09/14/stifel-nicolaus-boosts-newlink-genetics-corporation-nlnk-price-target-to-29-00.html.

Several hedge funds and other institutional investors have recently modified their holdings of NLNK. State of Wisconsin Investment Board purchased a new position in shares of NewLink Genetics Corporation during the second quarter worth about $125,000. Trexquant Investment LP grew its holdings in shares of NewLink Genetics Corporation by 39.1% during the second quarter. Trexquant Investment LP now owns 18,132 shares of the biotechnology company’s stock worth $133,000 after purchasing an additional 5,097 shares in the last quarter. Advisor Group Inc. grew its holdings in shares of NewLink Genetics Corporation by 3.4% during the second quarter. Advisor Group Inc. now owns 18,082 shares of the biotechnology company’s stock worth $133,000 after purchasing an additional 600 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of NewLink Genetics Corporation by 3.0% during the second quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock worth $140,000 after purchasing an additional 556 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. purchased a new position in shares of NewLink Genetics Corporation during the first quarter worth about $145,000. 54.78% of the stock is owned by institutional investors.

About NewLink Genetics Corporation

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Analyst Recommendations for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.